SecBot SecBot
DEFA14A ·Filed Jun 30, 2026

CPRX

CATALYST PHARMACEUTICALS, INC.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001193125-26-290840
Proxy solicitation materials
Actionable Insight • Neutral

The merger vote is the key catalyst on July 8. Monitor for ISS/Glass Lewis recommendations and any additional shareholder lawsuits that could delay closing. The supplemental disclosures are unlikely to change the vote outcome given management's ~5.5% ownership and the premium offer.

DirectionNeutral
Confidencehigh
Horizondays

Drugs in focus

CPRX drug pipeline →

AGAMREE

● Neutral Named in this DEFA14A
Impact
Phase
Approved
Time to market
Already approved and commercialized (US launch March 2024)
Next catalyst
None dated

What to watchFor a non-medical investor, AGAMREE is a commercial-stage asset already contributing meaningful revenue growth ($117M in 2025, guiding $140-150M for 2026). There's no binary FDA catalyst ahead, so the stock moves on quarterly sales execution and overall company performance. Watch quarterly AGAMREE revenue growth rates and any news about label expansion studies (DMD is the only approved indication). Multiple analysts downgraded CPRX to Hold/Neutral recently, suggesting the easy money from the approval catalyst is behind it.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$31.44
T+0 close · Jun 30, 2026 · via day close
Latest settled
+0.16%
T+5 · $31.49
Vs SPY
−0.10%
α at T+5
Next horizon
T+20
due 4mo ago
  1. T+0 · Jul 1 $31.44entry
  2. T+1 · 5mo ago +0.03%α +0.16% · $31.45
  3. T+5 · 4mo ago +0.16%α −0.10% · $31.49
  4. T+20 · due 4mo ago Pending
  5. T+60 · due 8w ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Catalyst Pharmaceuticals filed a DEFA14A supplement to its definitive proxy statement for the July 8, 2026 special meeting to vote on the $31.50/share all-cash acquisition by Angelini Pharma. The supplement voluntarily adds disclosures regarding a shareholder lawsuit (Seaward v. Catalyst) alleging inadequate proxy disclosures, additional background on merger negotiations with multiple parties, and financial projections. The company believes the lawsuit is without merit and the supplemental disclosures aim to mitigate litigation risk.

Key Financial Metrics

Vote
merger approval
Meeting
2026-07-08

Key Facts

  • Special meeting to vote on merger with Angelini Pharma scheduled for July 8, 2026; record date June 3, 2026.
  • One shareholder lawsuit filed June 10, 2026 in N.D. Illinois (Seaward v. Catalyst) alleging inadequate proxy disclosures; company believes claims are without merit.
  • Supplemental disclosures include December 2025 and March 2026 financial projections for FIRDAPSE, AGAMREE, and FYCOMPA revenue through 2035.
  • CEO Richard Daly proposed retention terms: $875,000 base salary, 80% annual bonus target, 2x base+target retention bonus (75% at year 1, 25% at year 2) with non-compete and waiver of Good Reason rights.
  • Required vote: majority of outstanding shares (61,208,729 votes); directors and officers beneficially own ~5.5% of shares.
  • Merger consideration is $31.50 per share in cash, with all unvested options and RSUs accelerating and cashing out.

Financial Impact

No new financial impact; merger consideration remains $31.50/share. Supplemental projections show 2026 total revenue of $669M (Dec 2025) or $635M (Mar 2026).

revenuemerger consideration

Risk Factors

  • Shareholder lawsuit could seek injunction delaying or blocking the merger, though company believes claims are without merit.
  • Additional demand letters or lawsuits may be filed before the special meeting.
  • Required vote threshold (majority of outstanding shares) means abstentions and broker non-votes count as 'against'.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-290840
Document: 0001193125-26-290840-index-headers.html0001193125-26-290840
Document: 0001193125-26-290840-index.html0001193125-26-290840
Document: 0001193125-26-290840.txt0001193125-26-290840

Track record

16 reports on CPRX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
  2. Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
  3. Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
  4. Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
  5. Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
  6. Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
  7. Jun 30, 202619w ago DEFA14A Neutral 3/10 Viewing Entry $31.44 No price data
  8. Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
  9. May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
  10. May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 30, 2026